By: IPP Bureau
Last updated : May 28, 2026 10:49 am
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
Supriya Lifescience Ltd reported a strong financial performance for Q4 and FY26, driven by robust demand across key therapeutic segments, improved capacity utilisation, and steady traction in regulated global markets.
The cGMP-compliant API manufacturer, which operates across anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic segments, has a presence in more than 120 countries worldwide.
For Q4 FY26, the company posted a 50.2 percent year-on-year rise in revenue from operations to Rs 276.53 crore, compared to Rs 184.11 crore in Q4 FY25. EBITDA increased to Rs 97.62 crore from Rs 67.58 crore in the corresponding quarter last year, while Profit After Tax (PAT) rose to Rs 74.23 crore against Rs 50.37 crore in Q4 FY25.
EBITDA margin for the quarter stood at 35.3 percent as compared to 36.7 percent in the year-ago period, while PAT margin came in at 26.8 percent versus 27.4 percent. Quarterly earnings per share (EPS) improved to Rs 9.22 from Rs 6.29.
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25. EBITDA stood at Rs 294.05 crore, registering a 12.8 percent growth over Rs 260.79 crore reported in FY25.
PAT for FY26 increased 11.3 percent to Rs 209.12 crore from Rs 187.96 crore in the previous financial year. EBITDA margin for FY26 stood at 35.5 percent compared to 37.4 percent in FY25, while PAT margin declined to 25.3 percent from 27 percent.
Dr. Satish Wagh, Executive Chairman and Whole Time Director of Supriya Lifescience Ltd, said, “During FY26, we continued to strengthen our manufacturing and R&D infrastructure through capacity enhancement initiatives, strategic land acquisitions, and progress at our Ambernath formulation facility.”
“The commercialisation of the Liquid Anesthetic product, advancement in our finished dosage capabilities, and continued focus on backward integration further strengthened the foundation of our business. With a diversified product portfolio, the company remains well positioned to drive sustainable long-term growth,” Dr Wagh added.